6533b830fe1ef96bd12965c4
RESEARCH PRODUCT
ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents
Giuseppe BrancatelliL. GrazioliPiero BoraschiT. HelmbergerJeong Min LeeB. Op De BeeckMaria Antonietta BaliRiccardo ManfrediEmanuele NeriStephen J. SkehanElmar M. MerkleChristoph J. ZechCelso MatosAhmed Ba-ssalamahValérie VilgrainC. BartolozziF. Caseiro AlvesWolfgang SchimaLuis Martí-bonmatísubject
Radiology Nuclear Medicine and ImagingDelphi TechniqueStatement (logic)030218 nuclear medicine & medical imaging0302 clinical medicineNuclear Medicine and ImagingDelphi techniqueAumento da ImagemDiagnosisMedicineImagerie médicale radiologie tomographiehealth care economics and organizationsNeuroradiologySettore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIAmedicine.diagnostic_testLiver CellLiver DiseaseContrast mediaLiver DiseasesLiver NeoplasmsBile DuctInterventional radiologyGeneral MedicineBiliary tract; Contrast media; Delphi technique; Liver; Magnetic resonance imaging; Radiology Nuclear Medicine and ImagingMagnetic Resonance ImagingLiverBiliary tractRadiology Nuclear Medicine and imagingLiver Neoplasm030220 oncology & carcinogenesisRadiologyRadiologyHumanRadiography AbdominalAdenomamedicine.medical_specialtyConsensuseducationReproducibility of ResultConsensuBiliary tract; Contrast media; Delphi technique; Liver; Magnetic resonance imaging; Adenoma Liver Cell; Bile Ducts; Consensus; Delphi Technique; Diagnosis Differential; Humans; Liver Diseases; Liver Neoplasms; Magnetic Resonance Imaging; Radiography Abdominal; Reproducibility of Results; Contrast MediaAdenoma Liver CellDiagnosis Differential03 medical and health sciencesMagnetic resonance imagingHumansAbdominalRessonância MagnéticaMeios de ContrasteComputer. Automationbusiness.industryReproducibility of ResultsMagnetic resonance imagingMr imagingClinical trialRadiographyDifferentialBiliary tractBile DuctsDifferential diagnosisbusinessdescription
Objectives: To develop a consensus and provide updated recommendations on liver MR imaging and the clinical use of liver-specific contrast agents. Methods: The European Society of Gastrointestinal and Abdominal Radiology (ESGAR) formed a multinational European panel of experts, selected on the basis of a literature review and their leadership in the field of liver MR imaging. A modified Delphi process was adopted to draft a list of statements. Descriptive and Cronbach’s statistics were used to rate levels of agreement and internal reliability of the consensus. Results: Three Delphi rounds were conducted and 76 statements composed on MR technique (n = 17), clinical application of liver-specific contrast agents in benign, focal liver lesions (n = 7), malignant liver lesions in non-cirrhotic (n = 9) and in cirrhotic patients (n = 18), diffuse and vascular liver diseases (n = 12), and bile ducts (n = 13). The overall mean score of agreement was 4.84 (SD ±0.17). Full consensus was reached in 22 % of all statements in all working groups, with no full consensus reached on diffuse and vascular diseases. Conclusions: The consensus provided updated recommendations on the methodology, and clinical indications, of MRI with liver specific contrast agents in the study of liver diseases. Key points: • Liver-specific contrast agents are recommended in MRI of the liver. • The hepatobiliary phase improves the detection and characterization of hepatocellular lesions. • Liver-specific contrast agents can improve the detection of HCC.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2016-04-01 |